The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2017 | Update on venetoclax combination trials for elderly AML from ASH 2017
There were impressive updates on venetoclax combination studies for elderly acute myeloid leukemia (AML) that are progressing at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA. Speaking from the meeting, Marina Konopleva, MD, PhD, from the University of Texas MD Anderson Cancer Center, Houston, TX, discusses the studies, including the combination of venetoclax with azacitidine/decitabine (NCT02203773), low-dose cytarabine (NCT02287233), and cobimetinib and idasanutlin (NCT02670044). Dr Konopleva explains the exciting data so far, highlighting the utility of these new treatments, which are much needed for elderly AML, where treatment options are very limited.
